* AC Immune SA ACIU.OQ ACIU.O is expected to show no
change in
quarterly revenue when it reports results on April 26
(estimated).
*
* Refinitiv's mean analyst estimate for AC Immune SA is for
a
loss of 23 rappen per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for AC Immune
SA is
$9, above its last closing price of $2.18.
This summary was machine generated April 24 at 15:27 GMT. All
figures in Swiss francs unless otherwise stated